References
- Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010 Jan 28;362(4):329–344. doi: 10.1056/NEJMra0909142
- Cummings JL, Wood AJJ. Alzheimer’s disease. N Engl J Med. 2004 Jul 1;351(1):56–67. doi: 10.1056/NEJMra040223
- Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014 Feb 19;311(7):682–691. doi: 10.1001/jama.2014.93
- Porsteinsson AP, Isaacson RS, Knox S, et al. Diagnosis of early Alzheimer’s disease: clinical practice in 2021. J Prev Alzheimers Dis. 2021;8(3):371–386. doi: 10.14283/jpad.2021.23
- Lee D, Clark ED, Antonsdottir IM, et al. A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease. Expert Opin Pharmacother. 2023 Mar 23;24(6):691–703. doi: 10.1080/14656566.2023.2195539
- Hampel H, Hardy J, Blennow K, et al. The amyloid-beta pathway in Alzheimer’s disease. Mol Psychiatry. 2021 Oct;26(10):5481–5503. doi: 10.1038/s41380-021-01249-0
- Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991 Oct;12(10):383–388. doi: 10.1016/0165-6147(91)90609-V
- Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992 Apr 10;256(5054):184–185. doi: 10.1126/science.1566067
- Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021 May 6;384(18):1691–1704. doi: 10.1056/NEJMoa2100708
- Koutsodendris N, Nelson MR, Rao A, et al. Apolipoprotein E and Alzheimer’s disease: findings, hypotheses, and potential mechanisms. Annu Rev Pathol. 2022 Jan 24;17(1):73–99. doi: 10.1146/annurev-pathmechdis-030421-112756
- Hong YJ, Kim CM, Lee JH, et al. Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals. Sci Rep. 2022 Aug 22;12(1):14307. doi: 10.1038/s41598-022-18325-2
- Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009 Oct;41(10):1088–1093. doi: 10.1038/ng.440
- Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA. 1997 Oct 22–29;278(16):1349–1356. doi: 10.1001/jama.1997.03550160069041
- Genin E, Hannequin D, Wallon D, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011 Sep;16(9):903–907. doi: 10.1038/mp.2011.52
- Michaelson DM. APOE epsilon4: the most prevalent yet understudied risk factor for Alzheimer’s disease. Alzheimers Dement. 2014 Nov;10(6):861–868. doi: 10.1016/j.jalz.2014.06.015
- Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993 Aug 13;261(5123):921–923. doi: 10.1126/science.8346443
- Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012 Aug 30;367(9):795–804. doi: 10.1056/NEJMoa1202753
- Chhatwal JP, Schultz SA, McDade E, et al. Variant-dependent heterogeneity in amyloid beta burden in autosomal dominant Alzheimer’s disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurol. 2022 Feb;21(2):140–152. doi: 10.1016/S1474-4422(21)00375-6
- Wiseman FK, Al-Janabi T, Hardy J, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci. 2015 Sep;16(9):564–574. doi: 10.1038/nrn3983
- Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999 Jul 8;400(6740):173–177. doi: 10.1038/22124
- Nimmo JT, Kelly L, Verma A, et al. Amyloid-beta and alpha-synuclein immunotherapy: from experimental studies to clinical trials. Front Neurosci. 2021;15:733857. doi: 10.3389/fnins.2021.733857
- Song C, Shi J, Zhang P, et al. Immunotherapy for Alzheimer’s disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18. doi: 10.1186/s40035-022-00292-3
- LEQEMBITM (lecanemab-irmb). package insert. Nutley (NJ): Eisai Inc.; 2023 [cited 2023 Feb 3]. Available from: https://www.leqembi.com/-/media/Files/Leqembi/Prescribing-Information.pdf?hash=3d7bf1a2-5db2-4990-8388-81086f415676
- Biogen. Biogen to realign resources for Alzheimer’s disease franchise 2024 [ updated Jan 31] [cited 2024 Feb 28]. Available from: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
- Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9(2):197–210. doi: 10.14283/jpad.2022.30
- van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023 Jan 5;388(1):9–21. doi: 10.1056/NEJMoa2212948
- Tolar M, Hey J, Power A, et al. Neurotoxic soluble amyloid oligomers drive alzheimer’s pathogenesis and represent a clinically validated target for slowing disease progression [review]. Int J Mol Sci. 2021;22(12):6355. doi: 10.3390/ijms22126355
- Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023 Aug 8;330(6):512–527. doi: 10.1001/jama.2023.13239
- Sperling RA, Jack CR Jr., Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s association research roundtable workgroup. Alzheimers Dement. 2011 Jul;7(4):367–385. doi: 10.1016/j.jalz.2011.05.2351
- ADUHELM® (aducanumab-avwa). package insert. Cambridge (MA): Biogen Inc.; 2022. https://www.biogencdn.com/us/aduhelm-pi.pdf
- Penninkilampi R, Brothers HM, Eslick GD. Safety and efficacy of anti-amyloid-beta immunotherapy in Alzheimer’s disease: a systematic review and meta-analysis. J Neuroimmune Pharmacol. 2017 Mar;12(1):194–203. doi: 10.1007/s11481-016-9722-5
- Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease. Ageing Res Rev. 2021 Jul;68:101339. doi: 10.1016/j.arr.2021.101339
- Salloway S, Chalkias S, Barkhof F, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022 Jan 1;79(1):13–21. doi: 10.1001/jamaneurol.2021.4161
- Loomis SJ, Miller R, Castrillo-Viguera C, et al. Genome-wide association studies of ARIA from the aducanumab phase 3 ENGAGE and EMERGE Studies. Neurology. 2024 Feb 13;102(3):e207919. doi: 10.1212/WNL.0000000000207919
- Reish NJ, Jamshidi P, Stamm B, et al. Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med. 2023 Feb 2;388(5):478–479. doi: 10.1056/NEJMc2215148
- Cummings J, Rabinovici GD, Atri A, et al. Aducanumab: Appropriate Use Recommendations Update. J Prev Alzheimer’s Dis. 2022 Apr 01;9(2):221–230. doi: 10.14283/jpad.2022.34
- Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: Appropriate use recommendations. J Prev Alzheimer’s Dis. 2023 Mar 27. doi: 10.14283/jpad.2023.30
- Solopova E, Romero-Fernandez W, Harmsen H, et al. Fatal iatrogenic cerebral beta-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer’s disease. Nat Commun. 2023 Dec 12;14(1):8220. doi: 10.1038/s41467-023-43933-5
- Favre HA, Powell WH. Nomenclature of organic chemistry. IUPAC recommendations and preferred names. Royal Society of Chemistry; 2013. https://iupac.qmul.ac.uk/BlueBook/
- Caltagirone C, Ferrannini L, Marchionni N, et al. The potential protective effect of tramiprosate (homotaurine) against Alzheimer’s disease: a review. Aging Clin Exp Res. 2012 Dec;24(6):580–587. doi: 10.1007/BF03654836
- Swanoski MT. Homotaurine: a failed drug for Alzheimer’s disease and now a nutraceutical for memory protection. Am J Health Syst Pharm. 2009 Nov 1;66(21):1950–1953. doi: 10.2146/ajhp080576
- Aisen PS, Saumier D, Briand R, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006 Nov 28;67(10):1757–1763. doi: 10.1212/01.wnl.0000244346.08950.64
- van Horssen J, Wesseling P, van den Heuvel LP, et al. Heparan sulphate proteoglycans in Alzheimer’s disease and amyloid-related disorders. Lancet Neurol. 2003 Aug;2(8):482–492. doi: 10.1016/S1474-4422(03)00484-8
- Gervais F, Chalifour R, Garceau D, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid. 2001 Jul;8(Suppl 1):28–35.
- Manzano S, Aguera L, Aguilar M, et al. A review on tramiprosate (homotaurine) in Alzheimer’s disease and other neurocognitive disorders. Front Neurol. 2020;11:614. doi: 10.3389/fneur.2020.00614
- Alzheon Inc. Alzheon launches with veteran team and funding to accelerate drug development in Alzheimer’s disease and other neurodegenerative disorders 2013. [cited 2023 Mar 14]. Available from: https://alzheon.com/alzheon-launches-with-veteran-team-and-funding-to-accelerate-drug-development-in-alzheimers-disease-and-other-neurodegenerative-disorders/
- Abushakra S, Porsteinsson A, Vellas B, et al. Clinical benefits of tramiprosate in Alzheimer’s disease are associated with higher number of APOE4 alleles: The “APOE4 gene-dose effect”. J Prev Alzheimers Dis. 2016;3(4):219–228. doi: 10.14283/jpad.2016.115
- Abushakra S, Porsteinsson A, Scheltens P, et al. Clinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer’s Disease suggest disease modification potential. J Prev Alzheimers Dis. 2017;4(3):149–156. doi: 10.14283/jpad.2017.26
- Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in mild-to-moderate Alzheimer’s disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011 Feb;7(1):102–111. doi: 10.5114/aoms.2011.20612
- Alzheon Inc. Sustained clinical effects of tramiprosate in APOE4/4 homozygous patients with Alzheimer’s disease over 130 weeks: results of phase 3 extension study. 2017 [cited 2023 Mar 14]. Available from: https://alzheon.com/clinical-effects-tramiprosate-apoe4-homozygotes-mild-moderate-alzheimers-disease-ad-sustained-130-weeks-results-phase-3-extension-study/
- Hey JA, Yu JY, Versavel M, et al. ClinicaL pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2018 Mar;57(3):315–333. doi: 10.1007/s40262-017-0608-3
- Alzheon Inc. An efficacy and safety study of ALZ-801 in APOE4/4 early AD subjects: ClinicalTrials.Gov. [ updated 2021 May 19; cited 2021 March 14]. Available from: https://ClinicalTrials.gov/show/NCT04770220
- Kocis P, Tolar M, Yu J, et al. Elucidating the Abeta42 anti-aggregation mechanism of action of tramiprosate in Alzheimer’s disease: integrating molecular analytical methods, pharmacokinetic and clinical data. CNS Drugs. 2017 Jun;31(6):495–509. doi: 10.1007/s40263-017-0434-z
- Hey JA, Kocis P, Hort J, et al. Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain. CNS Drugs. 2018 Sep;32(9):849–861. doi: 10.1007/s40263-018-0554-0
- Sinha S, Lopes DH, Bitan G. A key role for lysine residues in amyloid beta-protein folding, assembly, and toxicity. ACS Chem Neurosci. 2012 Jun 20;3(6):473–481. doi: 10.1021/cn3000247
- Usui K, Hulleman JD, Paulsson JF, et al. Site-specific modification of Alzheimer’s peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18563–18568. doi: 10.1073/pnas.0804758106
- Abushakra S, Hey J, Blennow K, et al., editors. OC27-Significant effects of oral ALZ-801 on plasma biomarkers of Alzheimer’s disease: 12-month interim analysis of phase 2 biomarker study in APOE4 carriers with early AD. In: 15th Conference Clinical Trials Alzheimer’s Disease; San Francisco, USA. The Journal of Prevention of Alzheimer’s Disease; 2022.
- Alzheon Inc. Biomarker effects of ALZ-801 in APOE4 carriers with early Alzheimer’s disease 2020 [ updated 2020 Sep 30 [cited 2023 Mar 14]. Available from: https://ClinicalTrials.gov/show/NCT04693520
- Abushakra S, Hey J, Blennow K, et al. Effects of oral ALZ-801, an amyloid oligomer inhibitor, on plasma biomarkers in APOE4 carriers with early Alzheimer’s disease: results of six-month interim analysis from a phase 2 biomarker study. Alzheimer’s Dementia. 2022;18(S10):e069141. doi: 10.1002/alz.069141
- Hey J, Abushakra S, Blennow K, et al. Effects of ALZ-801, an oral amyloid oligomer inhibitor, on biomarkers of Alzheimer’s disease (AD): 12-month results of phase 2 biomarker study in early AD (S26.007). Neurology. 2023;100(17_supplement_2):3243. doi: 10.1212/WNL.0000000000203129
- Alzheon. Alzheon reports industry-leading biomarker, brain preservation and clinical benefits following 24 months of treatment in phase 2 trial of oral ALZ-801 (valiltramiprosate) in patients with early Alzheimer’s disease. 2023 [cited 2024 Feb 28]. Available from: https://alzheon.com/alzheon-reports-industry-leading-biomarker-brain-preservation-and-clinical-benefits-following-24-months-of-treatment-in-phase-2-trial-of-oral-alz-801-valiltramiprosate-in-patients-with-early-alzhei/
- Alzheon Inc. Alzheon reports industry-leading disease modifying effects from phase 2 biomarker trial of oral tablet ALZ-801 (valiltramiprosate) in patients with early Alzheimer’s disease. 2022 [cited 2023 Mar 14]. Available from: https://alzheon.com/alzheon-reports-industry-leading-disease-modifying-effects-from-phase-2-biomarker-trial-of-oral-tablet-alz-801-valiltramiprosate-in-patients-with-early-alzheimers-disease/
- Alzheon Inc. Alzheon to present industry-leading biomarker, brain preservation, and clinical effects with oral ALZ-801 (valiltramiprosate). In: 15th Annual Clinical Trials in Alzheimer’s Disease Conference; 2022 [cited 2023 Mar 14]. Available from: https://alzheon.com/alzheon-to-present-industry-leading-biomarker-brain-preservation-and-clinical-effects-with-oral-alz-801-valiltramiprosate-at-15th-annual-clinical-trials-in-alzheimers-disease-conference/
- Abstract: 15th Conference Clinical Trials Alzheimer’s Disease. November 29- December 2, 2022, San Francisco, USA: Symposia - Oral Communications - Late Breaking News. J Prev Alzheimers Dis. 2022;9(S1):S8–S50.
- Alzheon Inc. Alzheon announces early completion of enrollment of apolloe4 phase 3 clinical trial evaluating oral ALZ-801 (valiltramiprosate) in APOE4/4 homozygotes with early Alzheimer’s disease. 2022 [cited 2023 Mar 14]. Available from: https://alzheon.com/alzheon-announces-early-completion-of-enrollment-of-apolloe4-phase-3-clinical-trial-evaluating-oral-alz-801-valiltramiprosate-in-apoe4-4-homozygotes-with-early-alzheimers-disease/
- Fan L, Mao C, Hu X, et al. New insights into the pathogenesis of Alzheimer’s disease. Front Neurol. 2019;10:1312. doi: 10.3389/fneur.2019.01312
- Yu L, Boyle PA, Nag S, et al. APOE and cerebral amyloid angiopathy in community-dwelling older persons. Neurobiol Aging. 2015 Nov;36(11):2946–2953. doi: 10.1016/j.neurobiolaging.2015.08.008
- Piazza F, Caminiti SP, Zedde M, et al. Association of microglial activation with spontaneous ARIA-E and CSF levels of anti-abeta autoantibodies. Neurology. 2022 Sep 20;99(12):e1265–e1277. doi: 10.1212/WNL.0000000000200892
- Kokjohn TA, Maarouf CL, Roher AE. Is Alzheimer’s disease amyloidosis the result of a repair mechanism gone astray? Alzheimers Dement. 2012 Nov;8(6):574–583. doi: 10.1016/j.jalz.2011.05.2429